Directorate Change

Stem Cell Sciences plc
18 December 2006


Embargoed until 07.00                                           18 December 2006

                    Board Changes at Stem Cell Sciences plc
                  ("Stem Cell Sciences", "SCS" or "the Group")


Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on
the commercialisation of stem cells and stem cell technologies in research and
novel cell-based therapies, today announces that David A. Dodd is to become
Non-Executive Chairman with Michael Dexter stepping down to become a
Non-Executive Director effective 1st January 2007.

Mr Dodd, who joined the Group as a Non-Executive Director in October 2006, has
significant commercial and corporate life sciences experience having held a
number of executive positions with companies such as Serologicals Corporation,
Solvay Pharmaceuticals, Wyeth, Bristol-Myers Squibb and Abbott Laboratories.

Dr Dexter, who joined the Group as Chairman in 2003, has played a key role in
the evolution of SCS over the past three years but feels that the time is right
to make way for someone with more commercial experience of the market place in
which the Group is positioning itself.

Commenting on the transition, Dr Dexter said:

"I have greatly enjoyed my time as Chairman of Stem Cell Sciences and, over the
past three years, I have had the privilege of working alongside an excellent 
management team to ensure that SCS has a sound scientific base from which 
to build and progress. The appointments throughout 2006 of Jeremy Scudamore and
David Dodd have further strengthened our Non-Executive Board and have brought a
wealth of industry and commercial experience to the Group. However, I feel 
that, at this strategic juncture, the Group will be better served by a Chairman
who has a more intimate knowledge of the commercialisation process involved in
the biotechnology environment. The Board has unanimously agreed that David meets
this criteria and I wish him every success in the role of Chairman."

Commenting on his appointment to Chairman, David Dodd said:

"Since joining SCS in October 2006 I have been impressed with the dedication and
commitment of everyone at the Group and am excited at what the future holds. The
stem cell industry is undergoing significant change and it is mine and the
Board's aim to ensure that Stem Cell Sciences plc is at the forefront of
continued advances within the sector, providing high value products and services
while enhancing the value of the Company for investors, customers and
employees."

Stem Cell Sciences continue to pursue the option of a dual listing on the
Australian Exchange and will update the market on how this is progressing in due
course.

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc
Peter Mountford, President and CEO                                 0131 662 9829
Hugh Ilyine, Vice President and Chief Operating Officer
Sue Furber, Director of Finance & Company Secretary

Weber Shandwick | Square Mile
Louise Robson or James White                                       020 7067 0700

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,
established in Melbourne, Australia in 1994, providing products in the
burgeoning stem cell research and drug discovery markets, in addition to the
targeted development of cell-based therapies for neurodegenerative disease and
injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics. SCS
principal focus is in neurological disease. Revenues in the neurotech market,
including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110
billion (Neurotech Insights, Volume 2/3 April 30 2006).

SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(R) provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, part of
Millipore Corporation.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies' goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchenne Muscular Dystrophy in 2007-8.

For further information on the company please visit:
www.stemcellsciences.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange